EMVision Medical Devices Dirección

Dirección controles de criterios 3/4

El CEO de EMVision Medical Devices es Scott Kirkland , nombrado en Jul 2023, tiene una permanencia de 1.33 años. compensación anual total es A$557.06K, compuesta por 56.5% salario y 43.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 5% de las acciones de la empresa, por valor de A$8.06M. La antigüedad media del equipo directivo y de la junta directiva es de 2.8 años y 5.4 años, respectivamente.

Información clave

Scott Kirkland

Chief Executive Officer (CEO)

AU$557.1k

Compensación total

Porcentaje del salario del CEO	56.5%
Permanencia del CEO	1.3yrs
Participación del CEO	5.0%
Permanencia media de la dirección	2.8yrs
Promedio de permanencia en la Junta Directiva	5.4yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Scott Kirkland en comparación con los beneficios de EMVision Medical Devices?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	AU$557k	AU$315k	-AU$3m
Mar 31 2024	n/a	n/a	-AU$3m
Dec 31 2023	n/a	n/a	-AU$3m
Sep 30 2023	n/a	n/a	-AU$4m
Jun 30 2023	AU$285k	AU$258k	-AU$4m
Mar 31 2023	n/a	n/a	-AU$4m
Dec 31 2022	n/a	n/a	-AU$5m
Sep 30 2022	n/a	n/a	-AU$5m
Jun 30 2022	AU$270k	AU$245k	-AU$6m
Mar 31 2022	n/a	n/a	-AU$7m
Dec 31 2021	n/a	n/a	-AU$7m
Sep 30 2021	n/a	n/a	-AU$8m
Jun 30 2021	AU$262k	AU$240k	-AU$8m
Mar 31 2021	n/a	n/a	-AU$7m
Dec 31 2020	n/a	n/a	-AU$5m
Sep 30 2020	n/a	n/a	-AU$4m
Jun 30 2020	AU$224k	AU$205k	-AU$3m
Mar 31 2020	n/a	n/a	-AU$3m
Dec 31 2019	n/a	n/a	-AU$3m
Sep 30 2019	n/a	n/a	-AU$3m
Jun 30 2019	AU$213k	AU$150k	-AU$3m
Mar 31 2019	n/a	n/a	-AU$3m
Dec 31 2018	AU$45k	AU$41k	-AU$2m

Compensación vs. Mercado: La compensación total ($USD362.22K) de Scott está en línea con el promedio de empresas de tamaño similar en el mercado Australian ($USD298.55K).

Compensación vs. Ingresos: La compensación de Scott ha aumentado mientras la empresa no es rentable.

CEO

Scott Kirkland

1.3yrs

Permanencia

AU$557,063

Compensación

Mr. Scott Kirkland has been an Executive Director of EMvision Medical Devices Limited since July 11, 2017 and serves as its Chief Executive Officer and Managing Director since July 01, 2023. Mr. Kirkland h...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Scott Kirkland	CEO, MD & Executive Director	1.3yrs	AU$557.06k	5% A$ 8.1m
Emma Waldon	CFO & Company Secretary	7.3yrs	sin datos	1.36% A$ 2.2m
Forough Khandan	Chief Technology Officer	1.8yrs	sin datos	sin datos
Stuart Crozier	Chairman of Clinical Advisory Board & Chief Scientific Officer	3.9yrs	sin datos	1.22% A$ 2.0m
Robert Tiller	Head of Design	3.8yrs	sin datos	sin datos
Konstanty Bialkowski	Head of Tech Development	no data	sin datos	sin datos
Christian Wight	Head of Regulatory Affairs	1.6yrs	sin datos	sin datos

2.8yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de EMV se considera experimentado (2.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Scott Kirkland	CEO, MD & Executive Director	7.3yrs	AU$557.06k	5% A$ 8.1m
Stuart Crozier	Chairman of Clinical Advisory Board & Chief Scientific Officer	5.4yrs	sin datos	1.22% A$ 2.0m
Geoffrey Donnan	Ex-Officio Member of Clinical Advisory Board	2.7yrs	sin datos	sin datos
Philip Dubois	Independent Non-Executive Director	4.2yrs	AU$55.50k	0.056% A$ 89.5k
John Keep	Non-Executive Chairman	6.7yrs	AU$105.45k	2.42% A$ 3.9m
Geoffrey Richard Pocock	Non-Executive Director	6.7yrs	AU$55.50k	1.0% A$ 1.6m
Tony Keane	Independent Non-Executive Director	6.4yrs	AU$51.83k	0.70% A$ 1.1m
Michael O'Sullivan	Member of Clinical Advisory Board	5.4yrs	sin datos	sin datos
David Cook	Member of Clinical Advisory Board	5.4yrs	sin datos	sin datos
James Walsham	Member of Clinical Advisory Board	5.4yrs	sin datos	sin datos
Ken Mitchell	Member of Clinical Advisory Board	5.4yrs	sin datos	sin datos
Stephen Davis	Ex-Officio Member of Clinical Advisory Board	2.7yrs	sin datos	sin datos

5.4yrs

Permanencia media

Junta con experiencia: La junta directiva de EMV se considera experimentada (5.4 años de antigüedad promedio).

EMVision Medical Devices Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

EMVision Medical Devices Ltd, Annual General Meeting, Nov 14, 2024

EMVision Medical Devices Ltd, Annual General Meeting, Nov 15, 2023

Less than half of directors are independent

EMVision Medical Devices Ltd, Annual General Meeting, Nov 16, 2022

Less than half of directors are independent

EMvision Medical Devices Limited Announces Clinical Advisory Board Appointments

Recent updates

EMVision Medical Devices Ltd, Annual General Meeting, Nov 14, 2024

Full year 2024 earnings released: AU$0.034 loss per share (vs AU$0.05 loss in FY 2023)

EMVision Unveils Backpack-Sized Brain Scanner to Empower First Responders

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

EMVision Medical Devices Ltd announced that it expects to receive AUD 15.281174 million in funding from Keysight Technologies, Inc.

EMVision Medical Devices Ltd announced that it expects to receive AUD 15.281174 million in funding from Keysight Technologies, Inc.

EMVision Medical Devices Ltd, Annual General Meeting, Nov 15, 2023

Full year 2023 earnings released: AU$0.05 loss per share (vs AU$0.081 loss in FY 2022)

New minor risk - Financial data availability

Emvision Medical Devices Limited Receives $1.75 Million Manufacturing Grant Award

No longer forecast to breakeven

EMVision Medical Devices Limited Provides an Update on Its Clinical Trial and Achievement of an Important Technical Development Milestone

EMVision Commences Clinical Trial

Less than half of directors are independent

EMVision Medical Devices Ltd Announces its Portable Brain Scanner Delivered to First Clinical Site

EMVision Medical Devices Ltd, Annual General Meeting, Nov 16, 2022

Full year 2022 earnings released: AU$0.081 loss per share (vs AU$0.12 loss in FY 2021)

Less than half of directors are independent

EMvision Medical Devices Limited Announces Clinical Advisory Board Appointments

Full year 2021 earnings released: AU$0.12 loss per share (vs AU$0.057 loss in FY 2020)

EMvision Medical Devices Limited provides an update on the build of its First Gen device

Medical Devices Limited Announces Australian Stroke Alliance in Collaboration with EMVision Wins Stage 2 MRFF Bid

New 90-day low: AU$2.74

EMvision Medical Devices Limited Announces FDA Provides De Novo Guidance

New 90-day low: AU$2.82

EMvision Medical Devices Limited Submits 513(G) Request for Information to the United States Food and Drug Administration

EMVision Medical Devices Limited Appoints Stuart Crozier as Chief Scientific Officer

New 90-day high: AU$3.85

New 90-day high: AU$3.30

New 90-day high: AU$2.74

EMvision Medical Devices Limited Announces Board Changes

New 90-day high - AU$2.40

Full year earnings released - AU$0.056 loss per share

New 90-day high - AU$1.94

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Miembros de la Junta

Permanencia media